<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88842">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651052</url>
  </required_header>
  <id_info>
    <org_study_id>2010-03</org_study_id>
    <nct_id>NCT01651052</nct_id>
  </id_info>
  <brief_title>Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000</brief_title>
  <official_title>Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational trial is to gather further clinical data to confirm the
      safety and performance of the Edwards Pericardial Aortic Bioprosthesis, Model 11000 in this
      trial population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, non-controlled observational clinical trial. Up to
      200 subjects will be enrolled at up to 6 participating clinical sites. The trial will
      include male and female patients, 18 years or older, requiring replacement for a diseased,
      damaged, or malfunctioning native or prosthetic valve. Patients will be followed and
      assessed after implant for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Intraoperative, discharge, 3 months, and annual scheduled follow-up visits (5 Years)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Descriptive information of early rates and late linearized rates of the follow-ing:
Structural valve deterioration
Thromboembolism
All bleeding/hemorrhage
Major bleeding/hemorrhage
All paravalvular leak
Major paravalvular leak
Non-structural valve dysfunction
Endocarditis
Hemolysis
All cause mortality
Trial valve-related mortality
Explant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance Endpoints</measure>
    <time_frame>5-Years (at each scheduled follow-up visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinically acceptable hemodynamic performance confirmed by core lab evaluation of echocardiography
New York Heart Association (NYHA) functional class com-pared to baseline
Change in Quality of Life questionnaires EQ-5D (EuroQol) and Short Form 12 version 2 (SF-12v2) from baseline/screening to 1-year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Valve Disorder</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Failure</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Aortic Bioprosthesis, Model 11000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aortic valve replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heart Valve Surgery</intervention_name>
    <description>Implant of an aortic valve, Model 11000</description>
    <arm_group_label>Aortic Bioprosthesis, Model 11000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Require replacement of aortic valve

          -  Signed informed consent

          -  Willing to return to study site for follow-up visits

        Exclusion Criteria:

          -  Active endocarditis/myocarditis (&lt; 3 months)

          -  Myocardial infarction (&lt; 30 days)

          -  Renal insufficiency/ End-stage renal disease

          -  Life expectancy (&lt; 1 year)

          -  Requires multiple valve replacement/repair

          -  Requiring emergent aortic valve surgery

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Renner</last_name>
    <role>Study Director</role>
    <affiliation>Edwards Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawła II</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im. Prymasa Tysiąclecia Stefana Kardynała Wyszyńskiego</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 4, 2013</lastchanged_date>
  <firstreceived_date>July 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve replacement/regurgitation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
